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Disclosures
 This speaker has no potential or 
actual conflicts of interest to disclose 
in relation to this presentation.
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Goals and Objectives
 Distinguish the etiologies and pathophysiology 
associated with the different WHO classification 
groups of pulmonary hypertension.
 Identify the pharmacological agents approved 
and under investigation for treatment of 
pulmonary arterial hypertension.
 Recognize the adverse drug reactions associated 
with the pharmacological agents used for 
treatment.
 Explain treatment algorithms for pulmonary 
arterial hypertension.
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Overview
 Pulmonary hypertension
 Management of pulmonary arterial hypertension 
(PAH) (Group 1)
 Management of chronic thromboembolic 
pulmonary hypertension (CTEPH) (Group 4)
 Pulmonary arterial hypertension approved drugs
 Pipeline
4
Pulmonary 
Hypertension
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Introduction
 Pulmonary hypertension (PH) is a disorder 
characterized by an increase in pulmonary artery 
pressure (PAP)
 Results from multifactorial pathophysiologic 
mechanisms with a wide variety in etiology
 Presentation can be nonspecific or attributed to 
comorbid conditions
Galiè N, et al. Eur Heart J. 2016;37:67-119.; Newman J. Am J Respir Crit Care Med. 2005;172(9):1072-1077.
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Epidemiology 
 Global reporting on the incidence of PH is limited 
 Around 1% of the global population suffers from PH
 PAH incidence levels range from 1.1 – 7.6 cases per 
one million per year; prevalence ranges from 6.6 –
26.0 cases per million per year
 CTEPH incidence rates are 0.9 cases per million per 
year; prevalence rates 3.2 cases per million per year
 The most common cause of PH is left heart disease 
(LHD)
Galiè N, et al. Eur Heart J. 2016;37:67-119.; Hoeper M, et al. Dtsch Arztebl Int. 2017;114: 73–84.; 
Hoeper M, et al. Lancet Respir Med 2016;4: 306–322; Thenappan T, et al. BMJ. 2018;360:j5492.
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Clinical Classifications
Pulmonary 
Hypertension 
WHO Group 1: 
Pulmonary 
arterial 
hypertension 
(PAH)
WHO Group 2:          
PH due to left 
heart disease
WHO Group 3:          
PH due to 
chronic lung 
disease and/or 
hypoxemia
WHO Group 4:          
PH due to 
chronic 
thromboembolic 
pulmonary 
hypertension 
WHO Group 5:          
PH due to 
unclear 
multifactorial 
mechanisms 
Adapted from: Lancet Respir Med 2016; 4:306–322.
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Conditions
 Group 1: PAH
 Idiopathic PAH (IPAH)
 Heritable
 Drugs and toxins
 Connective tissue disease
 Human immunodeficiency virus (HIV)
 Portal hypertension
 Congenital heart disease
 Schistosomiasis 
9
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Drugs and Toxins
Adapted from: Eur Heart J. 2016;37:67-119.
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Definite Likely Possible
Aminorex Amphetamine Cocaine
Fenfluramine Dasatinib Phenylpropanola
mine
Dexfenfluramine L-tryptophan St John’s Wort
Rapeseed oil Methamphetamines Amphetamine-
like drugs
Benfluorex Interferon alpha 
and Beta
Selective serotonin 
reuptake inhibitors
Alkylating 
agents
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 2: Left heart disease (LDH)
 Left ventricular systolic dysfunction
 Left ventricular diastolic dysfunction
 Valvular disease
 Congenital/acquired left heart inflow/outflow 
tract obstruction and congenital 
cardiomyopathies
 Congenital/acquired pulmonary veins 
stenosis
11
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 3: Lung disease/hypoxemia
 Chronic obstructive pulmonary disease
 Interstitial lung disease
 Other pulmonary diseases with mixed 
restrictive and obstructive pattern
 Sleep-disordered breathing
 Alveolar hypoventilation disorders
 Chronic exposure to high altitude
 Developmental lung diseases
12
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 4: Chronic thromboembolic 
pulmonary hypertension (CTEPH)
13
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 5: Unclear multifactorial 
mechanisms 
 Hematologic disorders
 Systemic disorders
 Metabolic disorders
 Others
14
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Blood Flow Through the 
Cardiopulmonary Anatomy
 Vena Cava  Right Atrium  Right Ventricle 
Pulmonary Artery  Pulmonary Capillaries 
Pulmonary Vein  Left Atrium  Left Ventricle 
Aorta  Systemic circulation
https://www.teachpe.com/anatomy-physiology/the-
circulatory-system/the-heart
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Hemodynamic Definitions:
 PH: Elevation of pulmonary arterial pressure 
(PAPm) ≥ 25 mmHg at rest
 All groups 
 Pre-capillary PH: PAPm ≥ 25 mmHg and 
pulmonary arterial wedge pressure (PAWP) ≤ 15 
mmHg 
 Associated Groups: 1, 3, 4 & 5
 Post-capillary PH: PAPm ≥ 25 mmHg and PAWP > 
15 mmHg 
 Associated Groups: 2, 5
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Pathophysiology
Calcium 
Signaling
Vasoactive 
Factor 
Imbalance
Inflammatory 
Mediators
Growth Factors
Extracellular Matrix 
Changes
Vascular Remodeling
Genetic Mutation
Toshner M, et al. Br Med Bull. 2010;94:21-32.
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3 Major Pathways  
↑ Endothelin-1
↑ binding on 
Endothelin A & B 
receptors
↑ ↑ ↑
vasoconstriction 
& proliferation
↓Prostaglandin 
I2
↓ cAMP 
↑ ↑ ↑
vasoconstriction 
& proliferation
Smooth 
Muscle Cell
Endothelin Nitric Oxide Prostacyclin
Toshner M, et al. Br Med Bull. 2010;94:21-32.; Humbert M, et al. N Engl J Med.2004;351:1425-1436.
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↓ Nitric Oxide
↓ NO-sCG 
binding 
↓ cGMP 
↑ ↑ ↑
vasoconstriction 
& proliferation
Clinical Presentation
 Early Stages
 Symptoms are non-specific, initially induced by 
exertion: 
• shortness of breath, fatigue, weakness, angina and 
syncope
 Advanced Stages
 Abdominal distension, hepatomegaly, jugular 
venous pressure, edema 
 Presentation of PH may be modified by diseases 
that cause or are associated with PH as well as 
other concurrent diseases
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Diagnosis
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Suspected PH
Echocardiogram 
(ECHO)
LHD/LD-PH diagnosis: 
Chest X-Ray
Pulmonary function tests
High resolution CT scan
Ventilation/perfusion 
Scan 
CTEPH 
Possible
Right Heart 
Catheterization
PAH 
Possible
Treat 
underlying 
disease
Consider 
other causes
High/intermediate Low
Confirmed
Not Confirmed
Positive
Normal
PAPm ≥ 25 mmHg 
PAWP ≤ 15 mmHg 
Targeted Treatment?
WHO Group
Group 1 Pulmonary arterial 
hypertension
Yes
Group 2 Pulmonary hypertension due 
to left sided heart disease
No
Group 3 Pulmonary hypertension 
associated with lung disease 
or chronic hypoxemia
No
Group 4 Chronic thromboembolic
pulmonary hypertension and 
other pulmonary artery 
obstructions
Yes
Group 5 Pulmonary hypertension with 
unclear and/or multifactorial 
mechanism 
No
Dunlap, et al. Am Fam Physician. 2016;94(6):463-469
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Management of 
Pulmonary Arterial 
Hypertension (Group 1)
22
Evaluation of Disease 
Severity
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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World Health Organization Functional Classification (WHO-FC)
I • No resulting limitations of physical activity
• Ordinary physical activity does not cause undue fatigue or dyspnea, 
chest pain, or heart syncope
II • Slight limitation of physical activity
• Comfortable at rest
• Ordinary physical activity results in undue fatigue or dyspnea, chest 
pain, or heart syncope
III • Marked limitation of physical activity
• Comfortable at rest
• Less than ordinary physical activity causes undue fatigue or 
dyspnea, chest pain, or heart syncope
IV • Inability to carry on any physical activity without symptoms 
• Dyspnea/fatigue may be present at rest
• Physical activity increases discomfort
Adapted from: Eur Heart J. 2016;37:67-119
Evaluation of Disease 
Severity
Exercise capacity
 6-minute walking test 
(6MWT)
 Cardiopulmonary 
exercise testing (CPET)
Imaging
 ECHO
 CMR 
Hemodynamics
• Right atrial pressure 
(RAP)
• Cardiac Index (CI)
• Mixed venous oxygen 
saturation (SvO2)
Biochemical Markers
• NT-proBNP
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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PAH Risk Assessment
(Estimated 1-Year Mortality)
Eur Heart J. 2016;37:67-119
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Prognosis
Determinant Low risk (<5%) Intermediate risk (5-10%) High risk (>10%)
Clinical signs of 
right heart failure Absent Absent Present
Progression of 
symptoms No Slow Rapid
Syncope No Occasional Repeated
WHO-FC I, II III IV
6MWD > 440 m 165 - 440 m < 165 m
Cardiopulmonary 
exercise testing
Peak VO2 >15 
ml/min/kg
(>65 % predicted)
VE/VCO2 slope <36
Peak VO2 11–15 ml/min/kg
(35-65 % predicted)
VE/VCO2 slope 36-44.9
Peak VO2 <11 
ml/min/kg
(<35 % predicted)
VE/VCO2 slope ≥ 36
Imaging RA area < 18 cm
2
No pericardial effusion
RA area 18 - 26 cm2
No or minimal pericardial effusion
RA area > 26 cm2
pericardial effusion
Hemodynamics
RAP <8 mmHg
CI ≥ 2.5 L/min/m2
SvO2 > 65 %
RAP 8-14 mmHg
CI ≥ 2.0 -2.4 L/min/m2
SvO2 60-65 %
RAP >14 mmHg
CI <2.0 L/min/m2
SvO2 <60 %
Adapted from: Eur Heart J. 2016;37:67-119
PAH Treatment Goals 
 Maintain patients with in WHO-FC I-II
 Preserve 6MWT distance 
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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PAH Treatment
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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General Measures
 Fluid restrictions/ 
sodium 
restrictions
 Exercise training
 Influenza/ 
pneumococcal 
vaccination
 Contraceptive 
measures
Supportive 
Therapies
 Diuretics
 Supplemental O2
 Digoxin
 Anticoagulation
 Iron 
supplementation
↑ Nitric Oxide
↑ NO-sCG binding 
↑ cGMP 
↓ vasoconstriction 
& proliferation
PAH Treatment
Specific Drug Therapy
Endothelin-1
↓ binding on 
Endothelin A & B 
receptors
↓ vasoconstriction 
& proliferation
↑ Prostaglandin I2
↑ cAMP 
↓ vasoconstriction 
& proliferation
Endothelin 
Receptor 
Antagonists 
(ERAs)
NO +
+
Soluble 
guanylate 
cyclase (sCG)
Stimulators
Phosphodiesterase-5 
(PDE-5)
PDE-5 
inhibitors
+
Prostacyclin 
Analogs
Smooth Muscle 
Cell
Endothelin Nitric Oxide (NO) Prostacyclin
Galiè N, et al. Eur Heart J. 2016;37:67-119.; Toshner M, et al. Br Med Bull. 2010;94:21-32.; Humbert M, et al. N Engl J 
Med.2004;351:1425-1436.
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PAH Treatment Algorithm
Adapted from: Eur Respir J 2015; 46: 879–882. 
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Treatment
naïve 
patient 
Acute 
vasoreactivity test 
(IPAH/HPAH, Drug 
induced PAH)
Calcium channel 
blocker (CCB) 
therapy (tx)Vasoreactive
Non-Vasoreactive
WHO-FC II-III WHO-FC IV
Monotherapy Oral 
Combination tx Combination 
tx, including IV
Inadequate response
Double/triple sequential 
combination tx
Patient 
already on 
treatment
Inadequate 
response Lung transplant
PAH Treatment
Oral calcium channel blockers dosing:
 Nifedipine 120–240 mg total daily dose (TDD)
 Diltiazem 240–720 mg  TDD
 Amlodipine 20 mg TDD
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Management of Chronic 
Thromboembolic 
Pulmonary 
Hypertension
(Group 4)
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Etiology of CTEPH
 Major vessel thromboembolism causes pulmonary 
artery remodeling
 CTEPH has been reported with a cumulative 
incidence of 0.1–9.1% within the first 2 years 
after asymptomatic pulmonary embolisms (PE) 
event
 Other pulmonary artery obstructions can also 
lead to remodeling
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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CTEPH Treatment Goals 
 Remove obstructions
 Restore blood circulation in the lungs
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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CTEPH Treatment
• Pulmonary endarterectomy (PEA) is the treatment 
of choice
• Anticoagulants, diuretics, and O2 in cases of heart 
failure or hypoxemia
• Lifelong anticoagulation
• In symptomatic patients classified as having 
persistent/recurrent CTEPH after surgical 
treatment or with inoperable CTEPH, sCG 
stimulators are recommended
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Pulmonary Arterial 
Hypertension Approved 
Drugs
35
Endothelin Receptor 
Antagonists (ERAs)
Medication Ambrisentan Bosentan Macitentan
Route Oral Oral Oral
Mechanism of Action In PAH ↑ endothelin-1 (ET-1) concentrations, action of ET-1 at ETA 
receptors causes vasoconstriction and cell proliferation. Action at 
ETB receptors causes vasodilation, antiproliferation, and ET-1 
clearance.
Blocks the action of 
ET-1 at ETA receptor
Blocks the action of ET-1 at ETA  and ETB
receptor
Warnings/Precautions • Pregnancy category X (REMs Programs)
• Not recommended in breast feeding
• Liver toxicity
• ↓ Hemoglobin
• ↓ Sperm counts
• Fluid retention
Tracleer [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017; Letairis [prescribing 
information]. Foster City, CA:  Gilead Sciences, Inc; 2015; Opsumit [prescribing information]. South San Francisco, CA: Actelion 
Pharmaceuticals US, Inc; 2018
36
Letairis® (ambrisentan)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise ability and delay clinical worsening
• Used in combination with tadalafil to reduce the risks of disease 
progression and hospitalization for worsening PAH and to improve 
exercise ability
Initial Dose 5 mg PO daily
Adverse Drug 
Reactions (ADRs)
Common
• Peripheral edema
• Nasal 
congestion/sinusitis
• Flushing
Severe
• Embryo-fetal toxicity
• Fluid retention
• Decreased hemoglobin
Interactions • Cyclosporine (Max dose 5 mg)
Contraindications • Pregnancy 
• Idiopathic pulmonary fibrosis
Considerations • Medication guide & REMs requirement
• Tablets should not be split, crushed, or chewed 
FDA Approval 2007
Letairis [prescribing information]. Foster City, CA:  Gilead Sciences, Inc; 2015
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Tracleer® (bosentan)
Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability and decreases clinical worsening
• In pediatric patients aged ≥3 yo with idiopathic or congenital PAH to improve 
pulmonary vascular resistance (PVR)
Initial Dose • ≤ 12 yo: 2 mg/kg PO BID
• > 12 yo & > 40 kg: 62.5 mg PO BID x 4wks, then 125 mg PO BID 
• > 12 yo & < 40 kg: 62.5 mg PO BID 
Adverse Drug 
Reactions (ADRs)
Common
• Respiratory tract infections
• Pyrexia 
• Anemia 
Severe
• Embryo-fetal toxicity
• Hepatotoxicity
• Fluid retention
Interactions • Cyclosporine (contraindicated)
• Glyburide (contraindicated)
• Hormonal contraceptives
• CYP2C9 & CYP3A4 metabolites
Contraindications • Pregnancy 
• Use with Cyclosporine 
• Use with Glyburide 
• Hypersensitivity
Considerations • Medication guide & REMs requirement
• Available as film coated tablets and tablet for oral suspension
• Film coated tablets should not be split, crushed, or chewed 
• Missed doses should be taken ASAP unless the next dose is with in 6 hrs
FDA Approval 2001
Tracleer [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
38
Opsumit® (macitentan)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Reduces risk of disease progression and hospitalization
Initial Dose 10 mg PO daily
Adverse Drug 
Reactions (ADRs)
Common
• Anemia 
• Nasopharyngitis/pharyngitis
• Bronchitis
• Headache
• Influenza
• Urinary tract infection
Severe
• Embryo-fetal toxicity
• Hepatotoxicity
• Fluid retention
• Decreased hemoglobin
Interactions • Strong CYP3A4 inhibitors and inducers
Contraindications • Pregnancy 
Considerations • Medication guide & REMs requirement
• Tablets should not be split, crushed, or chewed 
FDA Approval 2013
Opsumit [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2018
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Soluble Guanylate Cyclase 
(sGC) Stimulators
Medication Riociguat
Route Oral
Mechanism of Action • Stimulates sGC via a different binding site, independent of NO.
• Sensitizes sGC to endogenous NO by stabilizing the NO-sGC 
binding.
• Overall, it stimulates the NO-sGC-cGMP pathway and leads to 
increased generation of cGMP with subsequent vasodilation.
Warnings/Precautions • Symptomatic hypotension
• Bleeding
• Pulmonary edema (in veno-occlusive disease)
Adempas [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013
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Adempas® (riociguat)
Indication Treatment of adults with PAH (WHO Group 1):
• Improves exercise capacity, WHO functional class and to delays 
clinical worsening
Treatment of CTEPH (WHO Group 4) after surgical treatment or in 
inoperable CTEPH 
• Improves exercise capacity and WHO functional class
Initial Dose 1 mg PO TID
Adverse Drug 
Reactions (ADRs)
Headache, dyspepsia/gastritis, dizziness, nausea, diarrhea, hypotension, 
vomiting, anemia, gastroesophageal reflux, constipation, embryo-fetal
toxicity
Interactions • Strong CYP and PGP/BCRP inhibitors: consider a starting dose of 0.5 
mg PO TID
• Antacids: separate administration by 1 hr
Contraindications • Phosphodiesterase (PDE) inhibitors
Considerations • REMs requirement & medication guide
• Not recommended in breast feeding
• If therapy is missed for ≥3 days, restart at lower dose
FDA Approval 2013
Adempas [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013
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Phosphodiesterase-5 
(PDE-5) Inhibitors 
Medication Sildenafil Tadalafil
Route Oral
Intravenous (IV)
Oral
Mechanism of Action • Inhibit PDE-5, preventing the breakdown of cGMP in smooth 
muscle cells
• Increased levels of cGMP induces vascular relaxation and 
vasodilation
Warnings/Precautions • Hearing impairment
• Vision impairment
• Pulmonary edema
Revatio [prescribing information]. New York, NY: Pfizer Labs; 2014; Adcirca [prescribing information]. Indianapolis, IN: Eli Lilly and 
Company; 2017
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Revatio® (sildenafil) 
Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability and delays clinical worsening
Dosage • Tablet/suspension: 5 mg-20 mg PO TID
• Injection: 2.5 mg or 10 mg as IV bolus TID
Adverse Drug 
Reactions (ADRs)
Epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea, rhinitis, 
priapism 
Interactions • Alpha blockers or amlodipine
• PDE-5 inhibitors
• CYP3A4 inhibitors (not recommended)
Contraindications • Use with nitrates
• Use with sCG stimulators
• Hypersensitivity
Considerations • Space doses 4-6 hours apart
• Available as 20 mg tablets, 10 mg/mL suspension, and 10 mg/12.5 mL single use
vial
FDA Approval 2005
Revatio [prescribing information]. New York, NY: Pfizer Labs; 2014
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Adcirca® (tadalafil) 
Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability 
Dosage 40 mg PO daily
Adverse Drug 
Reactions (ADRs)
Headache, flushing, myalgia, erythema, rhinitis, priapism 
Interactions • Alpha blockers or amlodipine
• Alcohol
• PDE-5 inhibitors
• CYP3A4 inhibitors (not recommended)
• Use with ritonavir requires dose adjustments
Contraindications • Use with nitrates
• Use with sCG stimulators
• Hypersensitivity
Considerations • Available as 20 mg tablets
• Administered with out regard to meals
• Dividing dose over the course of the day is not recommended
FDA Approval 2009
Adcirca [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2017
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Prostacyclin Analogs
Medication Eporostenol Illoprost Treprostinil Selexipag
Route IV continuous
infusion 
Inhalation • Oral
• Inhalation
• IV continuous
infusion 
• SC continuous
infusion 
Oral
Mechanism of Action Analogs of endogenous prostacyclin (PGI2):
• Promote direct vasodilation of pulmonary vasculature 
• Inhibit platelet aggregation
Warnings/Precautions • Risk of rebound pulmonary hypertension, doses should not be discontinued or 
changed abruptly 
• Increased risk of bleeding
• Vasodilation reactions 
Flolan [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2018;
Veletri [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2012;
Ventavis [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2013;
Remodulin [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2018;
Tyvaso [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016;
Orenitram [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016;
Uptravi [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
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Flolan® (epoprostenol)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Initiate intravenous infusion through a central venous catheter at 2 
ng/kg/min
• Change dose in 1-to 2-ng/kg/min increments at intervals of at least 
15 minutes based on clinical response
Adverse Drug 
Reactions (ADRs)
Common
• Dizziness
• Jaw pain
• Headache
• Musculoskeletal pain
• Nausea/vomiting
Severe
• Catheter occlusions
• Injection site infections
• Pump malfunctions
Interactions • Anticoagulants
• Antihypertensive
Contraindications • Heart failure with reduced ejection fraction
• Hypersensitivity
Considerations • Diluent used (sterile diluent vs pH 12 sterile diluent) affects stability
• Reconstituted solutions may be used immediately; otherwise must be 
refrigerated
• Requires protection from light
• Requires infusion pump 
FDA Approval 1995
Flolan [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2018
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Veletri® (epoprostenol)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Initiate intravenous infusion through a central venous catheter at 2 
ng/kg/min
• Increments at intervals sufficient to allow assessment of clinical
• response; intervals should be at least 15 minutes
Adverse Drug 
Reactions (ADRs)
Common
• Dizziness
• Jaw pain
• Headache
• Flu-like symptoms
• Nausea/vomiting
Severe
• Catheter occlusions
• Injection site infections
• Pump malfunctions
Interactions • Anticoagulants
• Antihypertensive
Contraindications • Heart failure due to severe left ventricular systolic dysfunction
• Pulmonary edema
• Hypersensitivity
Considerations • Must be used at temperatures > 77° F – 104° F  
• Infusion rate calculation
• Requires protection from light
• Requires infusion pump 
FDA Approval 2008
Veletri [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2012
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Ventavis® (iloprost)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves composite endpoint consisting of exercise tolerance, NYHA 
Class, and lack of deterioration
Initial Dose • Starting dose: 2.5 mcg 
• Maintenance dose: 5 mcg
• 6 to 9 doses (inhalations) daily
Adverse Drug 
Reactions (ADRs)
Common
• Vasodilation (flushing)
• Headache
• Insomnia
• Nausea/vomiting
• Hypotension 
• Flu syndrome
Severe
• Alkaline phosphatase increased
• Hemoptysis
• Pneumonia
• Pulmonary edema
Interactions • Anticoagulants
• Antihypertensive
Contraindications • None
Considerations • Requires use of I-neb® AAD® System
• Minimum of 2 hours between doses during waking hours
FDA Approval 2004
Ventavis [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2013
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Remodulin® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Diminishes symptoms associated with exercise
• Reduces rate of clinical deterioration, in patients who require 
transition from Flolan
Initial Dose New to therapy:
• 1.25 ng/kg/min; increase based on clinical response (increments of 
1.25 ng/kg/min/wk x4 wks, then 2.5 ng/kg/min/wk)
Transition from Flolan:
• Increase dose gradually as the Flolan dose is decreased
Adverse Drug 
Reactions (ADRs)
Common
• SC infusion site pain & reaction
• Headache
• Jaw pain
• Vasodilatation
• Edema
• Hypotension
Severe
• Hemoptysis
• Pneumonia
• GI hemorrhage
• Sepsis
Interactions • Anticoagulants
• Antihypertensive
• CYP2C8 inhibitors/inducers
Contraindications • None
Considerations • Indicated for SC or IV use only as a continuous infusion
• Use central catheter for IV route
FDA Approval 2002
Remodulin [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2018
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Tyvaso® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise ability
Initial Dose • Initial dosage: 3 breaths (18 mcg) per treatment session. If 3 breaths are not 
tolerated, reduce to 1 or 2 breaths
• Titrate to target maintenance dosage of 9 breaths or 54 mcg per treatment 
session as tolerated
Adverse Drug 
Reactions (ADRs)
Common
• Cough
• Headache
• Throat irritation
• Diarrhea 
• Edema
• Hypotension
Severe
• Hemoptysis
• Pneumonia
Interactions • Anticoagulants
• Antihypertensive
• CYP2C8 inhibitors/inducers
Contraindications • None
Considerations • Use only with the Tyvaso® Inhalation System
• Administer undiluted, as supplied
• Separate sessions approximately four hours apart, during waking hours
• Sterile solution for oral inhalation available in 2.9 mL ampule containing 1.74 
mg treprostinil (0.6 mg per mL)
FDA Approval 2009
Tyvaso [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016
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Orenitram® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Starting dose: 0.25 mg PO BID or 0.125 mg PO TID
• Titrate by 0.25 mg or 0.5 mg BID or 0.125 mg TID, not more than 
every 3 to 4 days as tolerated
• Maximum dose is determined by tolerability
Adverse Drug 
Reactions (ADRs)
Common
• Headache
• Nausea
• Diarrhea
Severe
• Hemoptysis
• Syncope
Interactions • Anticoagulants
• Antihypertensive
• CYP2C8 inhibitors/inducers
Contraindications • Severe hepatic impairment (Child Pugh Class C)
Considerations • Give with food 
• Swallow tablet whole; use only intact tablets
• Available as extended-release tablets: 0.125 mg, 0.25 mg, 1 mg & 
2.5 mg
• Should not be taken with alcohol
• Never discontinue abruptly
FDA Approval 2013
Orenitram [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016
51
Uptravi® (selexipag)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Delays disease progression and reduces the risk of hospitalization
Initial Dose • Starting dose: 200 mcg PO BID
• Increase the dose by 200 mcg BID at weekly intervals to the highest 
tolerated dose up to 1600 mcg BID
• Maintenance dose is determined by tolerability
Adverse Drug 
Reactions (ADRs)
Common
• Headache
• Diarrhea
• Jaw pain
• Nausea/vomiting
• Myalgia
• Pain in extremity
• Flushing
Severe
• Pulmonary edema 
Interactions • CYP2C8 inhibitors/inducers
Contraindications • Concomitant use with strong CYP2C8 inhibitors
Considerations • Tablet strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 
1200 mcg, 1400 mcg, 1600 mcg
• Avoid use in severe hepatic impairment
• Not recommended in breastfeeding
FDA Approval 2015
Uptravi [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
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Investigation
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Agents Under Investigation
BPS-314d-MR Phase 3 study; BPS-314d-MR + inhaled treprostinil (Tyvaso) in PAH
• Beraprost sodium 314d modified release tablets
• Prostacyclin analog
Bardoxolone Methyl Phase 3 study, bardoxolone methyl + standard of care in patients with 
WHO Group 1 connective tissue disease PAH
• Bardoxolone methyl, activator of NRF2  decrease in oxidative 
damage
Ubenimex Phase 2 study; treatment of PAH
• Ubenimex, an oral inhibitor of LTA4H, the enzyme responsible for the 
formation of the pro-inflammatory mediator LTB4
CXA-10 Phase 2 study; CXA-10 + background therapy in PAH
• CXA-10, nitrated fatty acid compound with multiple mechanisms of 
action
ABI-009 Phase 1 study
• ABI-009, mTOR inhibitor, for PAH
https://www.clinicaltrials.gov/ct2/show/NCT01908699?term=Beraprost+added-on+to+Tyvaso&rank=1;
https://reatapharma.com/our-science/pipeline/pivotal-programs/ctd-pah-bardoxolone/;
https://clinicaltrials.gov/ct2/show/record/NCT02664558?term=ubenimex+pulmonary&rank=1;
https://www.complexarx.com/pipeline;
https://clinicaltrials.gov/ct2/show/NCT02587325
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Test Question:
True or False: 
 The World Health Organization (WHO) 
classification for pulmonary hypertension is 
delineated as follows: 
 Group 1 – Pulmonary Arterial Hypertension
 Group 2 – Pulmonary hypertension due to left 
sided heart disease (LHD)
 Group 3 – Pulmonary hypertension due to 
lung disease or hypoxia (or both)
 Group 4 – Pulmonary hypertension with 
unclear multifactorial mechanisms
 Group 5 – Chronic thromboembolic pulmonary 
hypertension 
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Test Question:
 True or False: 
 Phosphodiesterase-5 inhibitors (PDE-5i) and 
soluble guanylate cyclase (sGC) stimulators 
are recommended for use as combination 
therapy for the treatment of pulmonary arterial 
hypertension (PAH).
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Test Questions:
 True or False: 
 The endothelin receptor antagonists 
ambrisentan, bosentan, and macitentan all 
have respective risk evaluation and mitigation 
strategy (REMS) programs due to the risk of 
causing embryo-fetal toxicity. 
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